• Definium outlined late-stage plans for DT120 ODT, its lead program, with five Phase 3 studies across generalized anxiety disorder and major depressive disorder.
• Three Phase 3 readouts are anticipated in 2026, framed as key catalysts for potential commercial opportunities in GAD and MDD.
• Cash, cash equivalents, and investments totaled USD 373.4 million as of March 31, 2026, with cash runway expected to extend into 2028.
• Phase 2b data highlighted a single 100 µg dose with a 21.9-point HAM-A improvement at Week 12, a 7.7-point placebo-adjusted difference, and 48% remission at Week 12.
• Pipeline also includes DT402, an R(-)-MDMA program in development for autism spectrum disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.